Treatment of malignant pheochromocytoma with 131I-MIBG: A long survival;Feocromocitoma maligno tratado con MIBG I131: Una larga supervivencia

Anales de Medicina Interna

Volumn 20, Issue 11, 2003, Pages 575-578

  Arias Martínez, Natividad ^b   Barbado Hernandez F J ^b   Couto Caro, R ^a   Gil Guerrero, L ^b   Coronado Poggio, M ^a   Navarro, T ^a   Gomez Cerezo J ^b   Casal Esteban, V ^b   Vazquez Rodriguez J J ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b NONE

Author keywords

Malignant pheochromocytoma; Metaiodobenzylguanidine; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; PRAZOSIN;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MALE; PHEOCHROMOCYTOMA; SURVIVAL TIME; SYMPTOM; TUMOR BIOPSY;

3-IODOBENZYLGUANIDINE; ADULT; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PHEOCHROMOCYTOMA; SURVIVORS;

EID: 0347512163     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Plouin, P-F; Gimenez-Roqueplo, A-P; La-Batide-Alanore, A; Salenave, S; Duclos, JM. Progres recents dans le diagnostic, l'evaluation pronostique et le traitement des pheochromocytomes. Rev Med Interne 2000; 21 (12): 1075-85.
2. Loh KC, Fitzgerald PA, Matthay KK, Yeo PPB, Price DC. The treatment of malignant pheochromocytoma with I 131 MIBG: A comprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20: 648-58.
3. Vazquez Rodriguez JJ. Enfermedades de la médula suprarrenal. En: M. Diaz-Rubio, D. Esquirós. Tratado de Medicina Interna. Ed Médica Panamericana. Madrid 1994. 2453-7.
4. Kopf, D Goretzki, PE; Lehnert, H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001; 127 (3): 143-55.
5. Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 1985; 7: 118-24.
6. Martín Hernández T, Serrano Olmedo I, Torres Cuadro A, Albero Tamarit A, Pineda A. Feocromocitoma maligno. Seguimiento en dos pacientes tratados con I 131 MIBG. Oncologia 1999; 22 (8): 381-7.
7. Krausz, Y. Nuclear endocrinology as a monitoring tool. Semin Nucl Med 2001; 31 (3): 238-50.
8. Hoefnagel CA. Radionuclide therapy revisited. Eur J Nucl Med 1992; 18: 408-31.
9. Sisson J, Shapiro B, Beierwaltes WH, Nakajo M, Glowniak J, Mangner T, Carey JE, Swanson DP, Copp J, Satterlee W, Wieland D. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 1983; 96: 209.
10. Troncone L, Rufini V, Daidone MS, De Santis M, Luzi S. I 131 metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. J Nucl Biol Med 1991; 35: 295-9.
11. Loh KC, Fitzgerald PA, Matthay KK, Yeo PPB, Price DC. The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131 I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 1997: 20: 648-58.
12. Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ et al. Treatment of malignant pheochromocytoma with 131 I metaiodobenzylguanidina: a French multicenterstudy. J Nucl Biol Med 1991; 35: 284-7.
13. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a serie of 20 patient with distant metastasis. J Endocrinol Invest 1992; 15: 631-42.
14. Bomanji J, Britton KE, Ur E, Hawkins L, Grossman AB, Besser GM. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131 I-metaiodobenzylguanidine. Nuclear Medicine Commnunications 1993; 14: 856-61.
15. Honda M, Uesugi K, Yamazaki H, Dezawa A, Mizuguchi K, Yamaji T, Ishibashi M. Malignant pheochromocytoma lacking clinical features of catecholamine excess until the late stage. Intern Med 2000; 39 (10): 820-825.
16. Yoshida S, Hatori M, Noshiro T, Kimura N, Kokubun S. Twenty six years' survival with multiple bone metastasis of malignant pheochromocytoma. Arch Orthop Trauma Surg 2001; 121 (10): 598-600.
17. Honda M, Uesugi K, Yamazaki H, Dezawa A, Mizuguchi K, Yamaji T, Ishibashi M. Malignant pheochromocytoma lacking clinical features of catecholamine excess until the late stage. Intern Med 2000; 39 (10): 820-5.